Clinical Trial

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-11-03; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2025-03-25
Status change: Not Yet Recruiting → Recruiting 2023-12-05
Trial Details
NCT Number NCT05610891
Lead Sponsor Cellectar Biosciences, Inc.
Collaborators: National Cancer Institute (NCI)
Conditions High-Grade Glioma
Enrollment 50 participants
Start Date 2023-10-01
Primary Completion 2026-05 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-18